Workflow
昊帆生物(301393) - 2023 Q4 - 年度财报
HIGHFINEHIGHFINE(SZ:301393)2024-04-08 16:00

Financial Performance - Net profit for the current period is ¥98,973,754.53, a decrease of 23.5% compared to ¥129,370,943.06 in the previous period[50]. - Cash flow from operating activities for the current period is ¥87,829,868.67, down 36.6% from ¥138,673,297.82 in the previous period[50]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in the last fiscal year, representing a growth of 15% year-over-year[119]. - Total operating revenue for 2023 was ¥388,794,947.08, a decrease of 13.1% compared to ¥447,457,811.11 in 2022[182]. - Basic and diluted earnings per share for 2023 were both ¥1.07, compared to ¥1.60 in 2022[183]. - The total equity increased to ¥2,129,084,007.67 in 2023 from ¥451,253,592.59 in 2022, showing a growth of 372%[182]. Research and Development - The company aims to develop new products, including liposome and lipid nanoparticle reagents, ionic liquids, PROTAC reagents, and nucleotide reagents, to meet customer demands and enhance its market position[27]. - The company emphasizes research and development as a priority, aiming to provide specialized chemical raw materials with higher synthesis technology barriers to support the pharmaceutical industry[28]. - The company has been granted 7 new invention patents in 2023, bringing the total to 38 patents, including 34 invention patents and 4 utility model patents[29]. - The company is investing heavily in R&D, with 150 million allocated for new technology development, aiming to enhance product efficiency and effectiveness[123]. - The company has engaged in various research projects, including over 120 published research papers and more than 30 authorized invention patents[100]. Production and Operations - The company plans to enhance production capacity and expand its product line, focusing on the construction of the Anhui Haofan production base project and potentially acquiring additional production bases[22]. - The company maintains a focus on optimizing production processes and developing new product technologies to enhance operational efficiency[28]. - The company has implemented a quality management system compliant with ISO9001 standards, ensuring stable production processes and reliable product quality[30]. - The company has a strong emphasis on sustainable development supported by its robust synthesis technology reserves[29]. Financial Position - The total current assets as of December 31, 2023, reached approximately CNY 1.96 billion, a significant increase from CNY 352.67 million at the beginning of the year, reflecting a growth of over 455%[163]. - Cash and cash equivalents amounted to CNY 1.74 billion, up from CNY 99.32 million, indicating a growth of approximately 1,754%[163]. - The company's fixed assets increased to CNY 212.35 million from CNY 116.78 million, representing an increase of about 81.8%[166]. - The total liabilities amounted to ¥46,461,176.10 in 2023, compared to ¥103,735,086.64 in 2022, indicating a significant reduction[182]. Market Strategy - The company plans to expand its market presence and enhance its product offerings through ongoing research and development initiatives[100]. - Market expansion plans include entering two new international markets, projected to increase market share by 5%[126]. - The company is considering strategic acquisitions to bolster its market position, with a budget of up to 300 million for potential targets[126]. - Future guidance indicates a focus on increasing operational efficiency and expanding into new markets, with specific targets to be outlined in subsequent reports[153]. Corporate Governance - The company has established a structured and efficient corporate governance framework, enhancing operational efficiency through clear responsibilities among various governance bodies[31]. - The company has engaged in discussions to enhance decision-making processes, ensuring the interests of minority shareholders are considered[63]. - The board of directors did not raise any objections regarding company matters during the reporting period, indicating a unified leadership approach[115]. - The company has established a compensation and assessment committee to determine the remuneration of directors and senior management based on internal policies[103]. Shareholder Information - The company’s major shareholder remains unchanged during the reporting period, with no new changes in control[82]. - The actual controller, Zhu Yong, holds a 48.04% stake in the company, ensuring significant influence over corporate decisions[149]. - The company has not conducted any repurchase transactions among the top ten shareholders during the reporting period[84].